MET and glioma: Single‐cell transcriptomic data suggest that the MET–STAT4–PD‐L1 axis may enforce glioma immune evasion while activation of the MET pathway induces upregulation of PD‐L1, revealing a potential treatment using a combination of MET and PD‐L1 inhibitors [213].